Methods and devices for providing prolonged drug therapy
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/20
A61K-009/00
A61K-009/24
A61K-009/50
A61K-009/70
A61K-031/00
A61K-031/137
A61K-031/421
A61K-031/4422
A61K-031/4458
출원번호
US-0638977
(2003-08-12)
등록번호
US-9029416
(2015-05-12)
발명자
/ 주소
Lam, Andrew C.
Shivanand, Padmaja
Ayer, Atul D.
Hatamkhany, Zahedeh
Gupta, Suneel K.
Guinta, Diane R.
Christopher, Carol A.
Saks, Samuel R.
Hamel, Lawrence G.
Wright, Jeri D.
Weyers, Richard G.
출원인 / 주소
Alza Corporation
대리인 / 주소
Baker & Hostetler LLP
인용정보
피인용 횟수 :
3인용 특허 :
95
초록▼
Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additi
Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
대표청구항▼
1. An osmotic dosage form comprising: a capsule-shaped longitudinally compressed tablet core containing a plurality of layers wherein drug is contained in at least one layer and at least one other layer comprises a suitable fluid-expandable polymer, and wherein said drug is a CNS-stimulant drug sele
1. An osmotic dosage form comprising: a capsule-shaped longitudinally compressed tablet core containing a plurality of layers wherein drug is contained in at least one layer and at least one other layer comprises a suitable fluid-expandable polymer, and wherein said drug is a CNS-stimulant drug selected from the group consisting of methylphenidate, d-threo-methylphenidate, amphetamine, dextroamphetamine, methamphetamine, and pemoline;a semipermeable wall surrounding said longitudinally compressed tablet core to thereby form a compartment having an osmotic gradient to drive fluid from an external fluid environment contacting said semipermeable wall into said compartment; andan orifice formed through said semipermeable wall and into said longitudinally compressed tablet core to permit drug to be released from within said compartment into said external fluid environment. 2. The dosage form described in claim 1 wherein said longitudinally compressed tablet core comprises two layers and wherein said orifice is formed through said semipermeable wall at a location adjacent to said layer wherein said drug is contained. 3. The dosage form described in claim 2 additionally comprising an immediate-release dose of a drug applied as a coating onto the outer surface of said osmotic dosage form. 4. The dosage form described in claim 1 wherein said longitudinally compressed tablet core comprises three layers and a portion of said drug is contained within a first layer and the remaining portion of said drug is contained within a second layer, wherein the concentration of drug contained within said first layer is less than the concentration of drug contained within said second layer, and wherein said fluid-expandable polymer is contained within a third layer and said orifice is formed through said semipermeable wall at a location adjacent to said first layer. 5. The dosage form described in claim 4 further comprising an immediate-release dose of a drug applied as a coating onto the outer surface of said osmotic dosage form. 6. The dosage form described in claim 1 wherein said CNS-stimulant drug is methylphenidate. 7. The dosage form described in claim 5 wherein said coating comprises an antidegradation agent. 8. The dosage form described in claim 7 wherein said antidegradation agent is phosphoric acid. 9. The dosage form described in claim 1 wherein said semipermeable membrane comprises cellulose acetate and a flux-enhancing agent. 10. The dosage form described in claim 9 wherein said flux-enhancing agent is a copolymer of ethylene and propylene oxide. 11. A dosage form comprising: a first drug layer comprising drug, wherein said drug is a CNS-stimulant drug selected from the group consisting of methylphenidate, d-threo-methylphenidate, amphetamine, dextroamphetamine, methamphetamine, and pemoline, or a pharmaceutically acceptable salt thereof;a second drug layer comprising an additional quantity of said drug, wherein the quantity of said drug in said second layer is greater than the quantity of said drug in the first layer;a third layer comprising a composition that expands and displaces the first drug layer followed by the second drug layer from the dosage form;a wall that surrounds the three layers, which wall is permeable to fluid and impermeable to drug; anda passageway in the wall communicating with the first drug layer for delivering the first drug layer followed by the second drug layer from the dosage form wherein said drug layers and wall are shaped and adapted to interact cooperatively such that drug is released from the dosage form at an ascending release rate beginning with a first periodic interval that begins at time t=0 and continuing up to at least about 5.5 hours following administration of said dosage form. 12. The dosage form of claim 11 wherein said drug is methylphenidate hydrochloride. 13. The dosage form of claim 11 further comprising a drug layer overcoat. 14. The dosage form of claim 11 wherein the third layer further comprises at least one osmagent. 15. The dosage form of claim 14 wherein at least about 35% of the third layer comprises an osmagent. 16. The dosage form of claim 15 wherein the osmagent is sodium chloride. 17. The dosage form of claim 11 wherein said wall further comprises an immediate-release dosage of the drug applied as a coating onto the outer surface. 18. The dosage form of claim 17 wherein the coating comprises an antidegradation agent. 19. The dosage form of claim 18 wherein the antidegradation agent is phosphoric acid. 20. The dosage form of claim 11 wherein said wall further comprises cellulose acetate and a flux-enhancing agent. 21. The dosage form of claim 20 wherein the flux enhancing agent is a copolymer of ethylene and propylene oxide. 22. A dosage form comprising a capsule shaped tablet core comprising two layers, wherein: a first of said two layers comprises a portion of drug, wherein the drug is methylphenidate or pharmaceutically acceptable salt thereof,a second of said layers comprises a suitable fluid-expanding polymer and is adjacent said first layer,a semipermeable membrane surrounding the capsule shaped tablet core to form a compartment having an osmotic gradient to drive fluid from an external fluid environment contacting the semipermeable membrane into the compartment, andan orifice formed through the semipermeable membrane and into the capsule shaped tablet core at a location adjacent to the first layer to permit the drug to be released from within the compartment into the external fluid environment, and wherein the dosage form releases the drug at an ascending release ratebeginning with a first periodic interval that begins at time t=0 and continuing up to at least about 5.5 hours following administration of said dosage form. 23. The dosage form of claim 22 wherein said drug comprises 100 ng and 500 mg of methylphenidate. 24. The dosage form of claim 22 that further comprises a drug layer overcoat. 25. The dosage form of claim 22 wherein the second layer further comprises at least one osmagent. 26. The dosage form of claim 22 that is a bi-layer dosage form comprising a drug layer and a push layer. 27. The dosage form of claim 26 wherein at least about 35% of the push layer comprises the osmagent. 28. The dosage form of claim 27 wherein the osmagent is sodium chloride. 29. The dosage form of claim 22 further comprising an outer surface and an immediate-release dosage of the drug applied as a coating onto the outer surface. 30. The dosage form of claim 29 wherein the coating comprises an antidegradation agent. 31. The dosage form of claim 30 wherein the antidegradation agent is phosphoric acid. 32. The dosage form of claim 22 wherein the semipermeable membrane further comprises cellulose acetate and a flux-enhancing agent. 33. The dosage form of claim 32 wherein the flux enhancing agent is a copolymer of ethylene and propylene oxide. 34. A method comprising orally administering an osmotic dosage form comprising: a capsule-shaped longitudinally compressed tablet core containing a plurality of layers wherein drug is contained in at least one layer and at least one other layer comprises a suitable fluid-expandable polymer, wherein said drug is methylphenidate hydrochloride;a semipermeable wall surrounding said longitudinally compressed tablet core to thereby form a compartment having an osmotic gradient to drive fluid from an external fluid environment contacting said semipermeable wall into said compartment; andan orifice formed through said semipermeable wall and into said longitudinally compressed tablet core to permit drug to be released from within said compartment into said external fluid environment. 35. A method comprising orally administering a capsule shaped dosage form comprising: a first drug layer comprising drug, wherein said drug is methylphenidate hydrochloride;a second drug layer comprising an additional quantity of said drug, wherein the quantity of said drug in said second layer is greater than the quantity of said drug in the first layer;a third layer comprising a composition that expands and displaces the first drug layer followed by the second drug layer from the dosage form;a wall that surrounds the three layers, which wall is permeable to fluid and impermeable to drug; anda passageway in the wall communicating with the first drug layer for delivering the first drug layer followed by the second drug layer from the dosage form wherein said drug layers and wall are shaped and adapted to interact cooperatively such that drug is released from the dosage form at an ascending release rate beginning with a first periodic interval that begins at time t=0 and continuing up to at least about 5.5 hours following administration of said dosage form. 36. A method comprising orally administering a dosage form comprising a capsule shaped tablet core comprising two layers, wherein: a first of said two layers comprises a portion of a drug, wherein said drug is methylphenidate hydrochloride,a second of said layers comprises a suitable fluid-expanding polymer and is adjacent said first layer,a semipermeable membrane surrounding the capsule shaped tablet core to form a compartment having an osmotic gradient to drive fluid from an external fluid environment contacting the semipermeable membrane into the compartment, andan orifice formed through the semipermeable membrane and into the capsule shaped tablet core at a location adjacent to the first layer to permit the drug to be released from within the compartment into the external fluid environment, and wherein the dosage form releases the drug at an ascending release ratebeginning with a first periodic interval that begins at time t=0 and continuing up to at least about 5.5 hours following administration of said dosage form. 37. A dosage form comprising a capsule shaped tablet core comprising: two layers, wherein a first of said two layers comprises a portion of drug, wherein said drug comprises-methylphenidate hydrochloride, and wherein a second of said layers comprises a suitable fluid-expanding polymer;a semipermeable membrane that surrounds the capsule shaped tablet core to form a compartment that has an osmotic gradient that drives fluid from an external fluid environment contacting the semipermeable membrane into the compartment; andan orifice that is formed through the semipermeable membrane at a location adjacent to the first layer that permits the drug to be released from the compartment into the external fluid environment,wherein the dosage form releases the drug over a period comprising a first, second, and third sequential time intervals of equal duration, andwherein the dosage form releases more of said drug during said second interval than during said first interval and more of said drug during said third interval than during said second interval. 38. The dosage form according to claim 37 wherein said period of release comprises a fourth sequential time interval, and wherein the dosage form releases more of said drug during said fourth interval than during said third interval. 39. The dosage form according to claim 37 further comprising an immediate-release dosage of the drug applied as a coating on an outer surface of the dosage form. 40. The dosage form according to claim 39 wherein the dosage form releases more of said drug during said second interval than during said first interval, not including drug released from said coating during said first interval. 41. The dosage form according to claim 40 wherein each of said time intervals is 30 minutes. 42. The dosage form according to claim 40 wherein each of said time intervals is 1 hour. 43. The dosage form according to claim 41 wherein the drug released during said first interval does not include any drug released from said capsule shaped tablet core. 44. The dosage form according to claim 42 wherein the drug released during said first interval does not include any drug released from said capsule shaped tablet core. 45. The dosage form according to claim 37 wherein said dosage form is configured for oral administration. 46. The dosage form according to claim 37 further comprising a third layer comprising an additional portion of said drug, wherein said third layer is disposed between said first layer and said second layer.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (95)
Misra Manjit K. (Ames IA) Shyy Yuh-Yuan (Ames IA), Acoustic and video imaging system for quality determination of pharmaceutical products.
Rudnic Edward M. (Gaithersburg MD) Belendiuk George W. (Potomac MD), Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine.
Weier Detlef (Heiligenberg DEX), Automatic sorting machine for sorting and classifying small products of the pharmaceutical and confectionery industries.
Dante Lee G. (Merion Station PA), Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhi.
Magruder Paul R. (Palo Alto CA) Barclay Brian (Menlo Park CA) Wong Patrick S. L. (Hayward CA) Theeuwes Felix (Los Altos CA), Composition comprising salbutamol.
Chen Chih-Ming (Cooper City FL) Lee Der-Yang (Plantation FL), Controlled release formulation for water soluble drugs in which a passageway is formed in situ.
Wong Patrick S. L. (Palo Alto CA) Barclay Brian L. (Sunnyvale CA) Deters Joseph C. (Los Altos CA) Theeuwes Felix (Los Altos CA), Controlled-release system with constant pushing source.
Urquhart John (Palo Alto CA) Theeuwes Felix (Los Altos CA), Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use.
Theeuwes Felix (1643 Fallen Leaf La. Los Altos CA 94022) Wong Patrick S.-L. (1371 Xavier Ave. Hayward CA 94545) Cortese Richard (20802 Laurel Rd. Los Gatos CA 95030) Eckenhoff James B. (1080 Autumn L, Dispenser comprising displaceable matrix with solid state properties.
Jordan Maureen L. (Mt. View CA) Ayer Atul D. (Palo Alto CA) Magruder Paul R. (Palo Alto CA) Edgren David E. (El Granada CA), Dosage form comprising fast agent delivery followed by slow agent delivery.
Ayer Atul D. (Palo Alto CA) Jordan Maureen L. (Mt. View CA) Magruder Paul R. (Mt. View CA) Edgren David E. (El Granada CA), Dosage form for delivering a drug at two different rates.
Jordan Maureen L. (Mt. View CA) Ayer Atul D. (Palo Alto CA) Magruder Paul R. (Palo Alto CA) Edgren David E. (El Granada CA), Dosage form for delivering acetaminophen or phenylpropanolamine.
Deters Joseph C. (Mountain View CA) Wong Patrick S. L. (Hayward CA) Barclay Brian L. (Sunnyvale CA) Theeuwes Felix (Los Altos CA) Swanson David R. (Palo Alto CA), Dosage form for dispensing drug for human therapy.
Wong Patrick S. (Palo Alto CA) Theeuwes Felix (Los Altos CA) Ayer Atul D. (Palo Alto CA) Kuczynski Anthony L. (Palo Alto CA), Dosage form for time-varying patterns of drug delivery.
Wong Patrick S. (Palo Alto CA) Theeuwes Felix (Los Altos CA) Ayer Atul D. (Palo Alto CA) Kuczynski Anthony L. (Palo Alto CA), Dosage form for time-varying patterns of drug delivery.
Edgren David E. (El Granada) Carpenter Howard A. (Palo Alto) Bhatti Gurdish K. (Fremont) Ayer Atul D. (Palo Alto CA), Dosage form for treating central nervous system disorders.
Hoover Charles E. (Sparta NJ) Dennin Randy J. (Greenwood SC) Gabor E. Allan (Summit NJ) Schobel Mark (Flemington NJ) Sorg Albert F. (Columbia NJ), Encapsulated dosage forms.
Theeuwes Felix (Los Altos CA) Wong Patrick S. L. (Hayward CA) Cortese Richard (Los Altos CA) Eckenhoff James B. (Los Altos CA), Juxtaposed laminated arrangement.
Riddle Thomas A. (San Francisco CA) Geerke Johan H. (Los Altos CA) Minton Keith P. (San Jose CA), Laser tablet treatment system with dual access to tablet.
Riddle Thomas A. (San Francisco CA) Geerke Johan H. (Los Altos CA) Minton Keith P. (San Jose CA), Laser tablet treatment system with dual access to tablet.
Wurtman Richard J. (Boston MA) Maher Timothy J. (Milton MA), Method and composition for enhancing the effect of indirect-acting sympathomimetic amines.
Gupta, Suneel K.; Guinta, Diane R.; Christopher, Carol A.; Saks, Samuel R.; Hamel, Lawrence G., Methods and devices for providing prolonged drug therapy.
Lam, Andrew C.; Shivanand, Padmaja; Ayer, Atul D.; Weyers, Richard G.; Gupta, Suneel K.; Guinta, Diane R.; Christopher, Carol A.; Saks, Samuel R.; Hamel, Lawrence G.; Wright, Jeri D.; Hatamkhany, Zah, Methods and devices for providing prolonged drug therapy.
Wong Patrick S. L. (Palo Alto CA) Theeuwes Felix (Los Altos CA) Eckenhoff James B. (Los Altos CA) Larsen Steven D. (Dublin CA) Huynh Hoa T. (Fremont CA), Multi-unit delivery system.
Bayer Gerald W. (Rochester NY) Diamantopoulos Paul A. (Rochester NY) Osterhoudt Hans W. (Spencerport NY) Schmit Paul F. (Rochester NY), Nitrate therapy for angina pectoris.
Baudier Philippe (Waterloo BEX) De Boeck Arthur (Herne BEX) Fossion Jacques (Braine-L\Alleud BEX), Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms.
Wong Patrick S. L. (Hayward CA) Barclay Brian (Sunnyvale CA) Deters Joseph C. (Mt. View CA) Theeuwes Felix (Los Altos CA), Osmotic device with dual thermodynamic activity.
Wong Patrick S. L. (Palo Alto CA) Theeuwes Felix (Los Altos CA) Barclay Brian L. (Sunnyvale CA) Dealey Michael H. (San Francisco CA), Osmotic dosage system for liquid drug delivery.
Zaffaroni Alejandro (Atherton CA) Michaels Alan S. (Atherton CA) Theeuwes Felix (Los Altos CA), Osmotic releasing device having a plurality of release rate patterns.
Zaffaroni Alejandro (Atherton CA) Michaels Alan S. (San Francisco CA) Theeuwes Felix (Los Altos CA), Osmotic releasing system with means for changing release therefrom.
Wong Patrick S.-L. (Hayward CA) Barclay Brian L. (Sunnyvale CA) Oeters Joseph C. (Mountain View CA) Theeuwes Felix (Los Altos CA), Osmotic system comprising plurality of members for dispensing drug.
Guittard George V. (Cupertino CA) Deters Joseph C. (Mountain View CA) Theeuwes Felix (Los Altos CA) Cortese Richard (San Jose CA), Osmotic system with instant drug availability.
Guittard George V. (Cupertino CA) Deters Joseph C. (Mountain View CA) Theeuwes Felix (Los Altos CA) Cortese Richard (San Jose CA), Osmotic system with instant drug availability.
Derleth Helmut (Nienburg DEX) Walter Ludwig (Hanover DEX) Bretz Karl-Heinrich (Nienburg DEX) Kurs Artur (Nienburg DEX), Process for preparing a substantially crystalline sodium aluminosilicate.
Panoz Donald (Tuckerstown BMX) Corneille Gilbert (Paris FRX), Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained the.
Cortese Richard (San Jose CA) Barclay Brian (Menlo Park CA) Theeuwes Felix (Los Altos CA), Simultaneous delivery of two drugs from unit delivery device.
Kochinke Frank (San Jose CA) Pfister William R. (Union City CA) Louie Jenny (Fremont CA) Arenson Dan (Escondido CA), Transdermal delivery systems for the modulated administration of drugs.
della Valle Francesco (Padua ITX) Toffano Gino (Montegrotto Terme ITX), Use of monosialoganglioside GM, to prevent the development of tolerance to the analgesic effect of morphine and related.
Mueller Karl F. (New York NY) Good William R. (Yorktown Height NY), Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.